Match tier
Listed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
A
Anupreet Kharbanda
Researcher
Also affiliated: Indian Institute of Technology Roorkee (2018)
Faculty Researcher
12 h-index
16 pubs
459 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Anupreet Kharbanda's research focuses on drug discovery and the development of novel therapeutic agents, particularly for cancer treatment. This work involves the identification and optimization of small molecules designed to inhibit specific protein kinases and disrupt cellular pathways implicated in cancer progression. Kharbanda has investigated inhibitors for targets such as FLT3, RET, TGFβR1, and NEK2, employing structure-based drug design methodologies. Publications also explore the potential of natural compounds like tocotrienols as anti-cancer agents and the use of programmable oligonucleotides, such as O'PROTACs, for targeted destruction of DNA-binding proteins. Kharbanda's research network includes collaborators Yuet-Kin Leung, Brendan Frett, Phuc Tran, and Xiuqi Wang from the University of Arkansas for Medical Sciences, with whom multiple publications have been co-authored. Kharbanda has an h-index of 12 and has published 16 papers with 451 citations.
Metrics
- h-index: 12
- Publications: 16
- Citations: 459
Selected Publications
-
Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy (2023)
-
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022)
-
Tocotrienols as an Anti-Breast Cancer Agent (2021)
-
Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG (2021)
-
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor (2021)
-
Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology (2021)
-
Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors (2021)
-
Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC (2021)
-
The Exploration of Chirality for Improved Druggability within the Human Kinome (2019)
-
Intramolecular cyclization of imidazo[1,2- <i>a</i> ]pyridines <i>via</i> a silver mediated/palladium catalyzed C–H activation strategy (2019)
-
Use of Imidazo[1,2‐<i>a</i>]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction (2019)
-
Catalyst free, C-3 functionalization of imidazo[1,2- <i>a</i> ]pyridines to rapidly access new chemical space for drug discovery efforts (2018)
-
Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives (2018)
Collaboration Network
Top Collaborators
Hongyu Li
University of Arkansas for Medical Sciences (US)
7 shared publications
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
Showing 5 of 7 shared publications
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
4 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Yuet‐Kin Leung
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Brendan Frett
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Wei Yan
University of Arkansas for Medical Sciences (US)
3 shared publications
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Phuc Tran
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Naga Rajiv Lakkaniga
Indian Institute of Technology Dhanbad (IN)
3 shared publications
- Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Yuqian Yan
Mayo Clinic (US)
2 shared publications
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Dejie Wang
Mayo Clinic in Arizona (US)
2 shared publications
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Yundong He
Mayo Clinic (US)
2 shared publications
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Yunqian Pan
Mayo Clinic in Arizona (US)
2 shared publications
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Haojie Huang
Mayo Clinic in Arizona (US)
2 shared publications
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Jaideep B. Bharate
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Xiuqi Wang
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Jingwei Shao
University of Arkansas for Medical Sciences (US)
1 shared publication
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Similar Researchers
Based on overlapping research topics
Baha’a Jabali
University of Arkansas for Medical Sciences
Drug Discovery
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Phuc Tran
University of Arkansas for Medical Sciences
Drug Discovery
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Brendan Frett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Structure-Activity Relationship
Jaideep B. Bharate
University of Arkansas for Medical Sciences
Drug Discovery
Cancer Treatment and Pharmacology
Computational Drug Discovery Methods
Erica Lane Smith
University of Arkansas for Medical Sciences
Drug Discovery
Cancer Treatment and Pharmacology
Neoplasms
K Ellis
University of Arkansas – Fort Smith
Cancer Treatment and Pharmacology
Neoplasms
Cancer-related molecular mechanisms research